EA200000816A1 - Применение 2-амино-6-трифторметоксибензотиазола для профилактики или лечения дисфункции мозжечка - Google Patents

Применение 2-амино-6-трифторметоксибензотиазола для профилактики или лечения дисфункции мозжечка

Info

Publication number
EA200000816A1
EA200000816A1 EA200000816A EA200000816A EA200000816A1 EA 200000816 A1 EA200000816 A1 EA 200000816A1 EA 200000816 A EA200000816 A EA 200000816A EA 200000816 A EA200000816 A EA 200000816A EA 200000816 A1 EA200000816 A1 EA 200000816A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prevention
treatment
triftorometoxibibenziaozol
sculvasus
amino
Prior art date
Application number
EA200000816A
Other languages
English (en)
Other versions
EA002676B1 (ru
Inventor
Андреес Боме
Ален Буаро
Тьерри Кантон
Ассунта Императо
Original Assignee
Авентис Фарма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фарма С.А. filed Critical Авентис Фарма С.А.
Publication of EA200000816A1 publication Critical patent/EA200000816A1/ru
Publication of EA002676B1 publication Critical patent/EA002676B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Применение рилузола или фармацевтически приемлемой соли этого соединения для получения лекарства, используемого для профилактики или лечения дисфункций мозжечка и, особенно, мозжечковых атаксий.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000816A 1998-02-06 1999-02-03 Применение 2-амино-6-трифторметоксибензотиазола для профилактики или лечения дисфункции мозжечка EA002676B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9801402A FR2774592B1 (fr) 1998-02-06 1998-02-06 Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
PCT/FR1999/000230 WO1999039710A1 (fr) 1998-02-06 1999-02-03 Application du 2-amino-6- trifluoromethoxy- benzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet

Publications (2)

Publication Number Publication Date
EA200000816A1 true EA200000816A1 (ru) 2001-02-26
EA002676B1 EA002676B1 (ru) 2002-08-29

Family

ID=9522673

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000816A EA002676B1 (ru) 1998-02-06 1999-02-03 Применение 2-амино-6-трифторметоксибензотиазола для профилактики или лечения дисфункции мозжечка

Country Status (18)

Country Link
US (1) US6245791B1 (ru)
EP (1) EP1052989B1 (ru)
JP (1) JP5127092B2 (ru)
KR (1) KR100574378B1 (ru)
AT (1) ATE245982T1 (ru)
AU (1) AU761978B2 (ru)
CA (1) CA2319686C (ru)
DE (1) DE69909970T2 (ru)
DK (1) DK1052989T3 (ru)
EA (1) EA002676B1 (ru)
ES (1) ES2199541T3 (ru)
FR (1) FR2774592B1 (ru)
IL (2) IL137608A0 (ru)
NO (1) NO327819B1 (ru)
NZ (1) NZ506124A (ru)
PT (1) PT1052989E (ru)
WO (1) WO1999039710A1 (ru)
ZA (1) ZA99740B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872739B1 (en) 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
US20220218673A1 (en) * 2018-05-27 2022-07-14 Biohaven Pharmaceutical Holding Company Ltd. Use of riluzole oral disintigrating tablets for treating diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2043070T3 (es) * 1988-12-15 1993-12-16 Rhone Poulenc Sante Procedimiento para la preparacion de derivados de la benzotiazolamina-2.
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
FR2726271B1 (fr) * 1994-10-26 1996-12-06 Rhone Poulenc Rorer Sa Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole

Also Published As

Publication number Publication date
WO1999039710A1 (fr) 1999-08-12
NO20003785L (no) 2000-07-24
AU761978B2 (en) 2003-06-12
JP5127092B2 (ja) 2013-01-23
US6245791B1 (en) 2001-06-12
NO327819B1 (no) 2009-09-28
EP1052989A1 (fr) 2000-11-22
KR100574378B1 (ko) 2006-04-26
DK1052989T3 (da) 2003-11-17
IL137608A0 (en) 2001-07-24
EP1052989B1 (fr) 2003-07-30
NZ506124A (en) 2003-07-25
FR2774592A1 (fr) 1999-08-13
PT1052989E (pt) 2003-12-31
AU2171199A (en) 1999-08-23
CA2319686C (fr) 2009-06-23
IL137608A (en) 2006-09-05
DE69909970D1 (de) 2003-09-04
CA2319686A1 (fr) 1999-08-12
FR2774592B1 (fr) 2000-03-17
ES2199541T3 (es) 2004-02-16
EA002676B1 (ru) 2002-08-29
ATE245982T1 (de) 2003-08-15
ZA99740B (en) 1999-08-02
KR20010040671A (ko) 2001-05-15
NO20003785D0 (no) 2000-07-24
DE69909970T2 (de) 2004-05-27
JP2002502819A (ja) 2002-01-29

Similar Documents

Publication Publication Date Title
ATE302770T1 (de) Benzimidazolverbindungen die nociceptinrezeptoraffinität haben
GB0225475D0 (en) Therapeutic agents
DK0920421T3 (da) Isoxazolinderivater anvendelige som antimikrobielle midler
WO2005021495A3 (en) Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
EE05094B1 (et) Kuluvate osade ssteem pinnaset””tlemismasina t””seadise jaoks
DK1071422T3 (da) Kombinationer af riluzol og levodopa til behandling af parkinsons sygdom
WO2003006893A3 (en) Methods of inhibiting amyloid toxicity
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
BG105197A (en) Polymorph form of a medicament
RS51003B (sr) Derivat piridin-1-oksida i postupak za njegovu transformaciju u farmaceutski efikasna jedinjenja
AU2002222180A1 (en) The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity
DE69923995D1 (de) Thiazol-derivate als ppar-gamma-ligande
WO2001041709A3 (en) Methods for treating cell death diseases and inflammation
DE69512310D1 (de) Glukopyranosid-Benzothiophene
EA200000816A1 (ru) Применение 2-амино-6-трифторметоксибензотиазола для профилактики или лечения дисфункции мозжечка
TW200420561A (en) Antimicrobial 1-aryl dihydropyridone compounds
ATE323493T1 (de) Gesteuerte freisetzung von antidepressiva
EA200100530A1 (ru) Комбинация рилузола с альфа-токоферолом
PL352119A1 (en) Derivatives of aminotetraline for treatment of cardiovascular diseases
HK1080768A1 (en) Use of epothilone derivatives for the treatment ofhyperparathyroidism
MXPA05009243A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados.
SV2001000202A (es) Uso de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina para el tratamiento del mal de parkinson
ECSP003725A (es) Metodo para tratar el mal de parkinson a travez de la administracion de (-) -5- ceto-2-n, n-d1-n-propilamino-tetrahidrotetralina
UY26405A1 (es) Método para tratar el mal de parkinson a través de la administración de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU